Multiple Myeloma

  • ID: 3797420
  • Report
  • 367 pages
  • Datamonitor Healthcare
1 of 3
Despite genericization of key brands, the multiple myeloma market is expected to continue to grow due to new product launches, label expansions, and rising disease prevalence.

This report addresses the following questions:

- What factors are contributing to the increase in prevalence of multiple myeloma?
- Which brands are the current market leaders in multiple myeloma?
- What impact will the approvals of pipeline therapies have on treatment patterns?
- How will genericization of Revlimid and Velcade impact the value of the overall lmarket over the forecast period?
- What are the most popular drug treatment regimens by patient segment in the US, Japan, and five major EU markets?
- In what patient population does there remain an unmet treatment need?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: MULTIPLE MYELOMA

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Darzalex (daratumumab)
- Empliciti (elotuzumab)
- Farydak (panobinostat)
- Keytruda (pembrolizumab)
- Kyprolis (carfilzomib)
- Ninlaro (ixazomib)
- Pomalyst (pomalidomide)
- Revlimid (lenalidomide)
- Selinexor
- Thalomid (thalidomide)
- Velcade (bortezomib)
- Primary Research Methodology

TREATMENT: MULTIPLE MYELOMA

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: MULTIPLE MYELOMA

- Executive Summary
- Disease Background
- Sources and Methodology Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: MULTIPLE MYELOMA

- Executive Summary
- Product Overview
- Product profile: Darzalex
- Product profile: Empliciti
- Product profile: Farydak
- Product profile: Kyprolis
- Product profile: Ninlaro
- Product profile: Pomalyst
- Product profile: Revlimid
- Product profile: Thalomid
- Product profile: Velcade

PIPELINE: MULTIPLE MYELOMA

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- Recently Discontinued Drugs
- Product profile (late stage): Aplidin
- Product profile (late stage): Keytruda
- Product profile (late stage): selinexor

APPENDIX

- Appendix: Epidemiology: Multiple Myeloma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll